The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://albietyyf344113.59bloggers.com/39203477/retatrutide-vs-tirzepatide-a-comparative-analysis